Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Stock Information for HealthWarehouse.com Inc

Loading

Please wait while we load your information from QuoteMedia.